0001567619-21-012382.txt : 20210617 0001567619-21-012382.hdr.sgml : 20210617 20210617200141 ACCESSION NUMBER: 0001567619-21-012382 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210615 FILED AS OF DATE: 20210617 DATE AS OF CHANGE: 20210617 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fu Tao CENTRAL INDEX KEY: 0001644888 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38205 FILM NUMBER: 211026658 MAIL ADDRESS: STREET 1: 3175 HANOVER STREET CITY: PALO ALTO STATE: CA ZIP: 94304 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Zai Lab Ltd CENTRAL INDEX KEY: 0001704292 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4560 JINKE ROAD STREET 2: BLDG. 1, 4F, PUDONG CITY: SHANGHAI STATE: F4 ZIP: 201210 BUSINESS PHONE: 862161632588 MAIL ADDRESS: STREET 1: 4560 JINKE ROAD STREET 2: BLDG. 1, 4F, PUDONG CITY: SHANGHAI STATE: F4 ZIP: 201210 4 1 doc1.xml FORM 4 X0306 4 2021-06-15 0 0001704292 Zai Lab Ltd ZLAB 0001644888 Fu Tao C/O ZAI LAB LIMITED 4560 JINKE ROAD, BLDG 1, 4TH FLOOR PUDONG, SHANGHAI F4 201210 CHINA 1 1 0 0 President & COO Ordinary Shares 2021-06-15 4 M 0 10000 18.92 A 217000 D Ordinary Shares 2021-06-15 4 S 0 2352 164.08 D 214648 D Ordinary Shares 2021-06-15 4 S 0 4564 164.80 D 210084 D Ordinary Shares 2021-06-15 4 S 0 1476 165.78 D 208608 D Ordinary Shares 2021-06-15 4 S 0 607 166.65 D 208001 D Ordinary Shares 2021-06-15 4 S 0 300 167.74 D 207701 D Ordinary Shares 2021-06-15 4 S 0 701 169.12 D 207000 D Ordinary Shares 107500 I See footnote Stock Options (Right to Buy) 18.92 2021-06-15 4 M 0 10000 0.00 D 2028-09-24 Ordinary Shares 10000 450000 D The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated March 17, 2021, expires September 15, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Reflects a weighted average sale price of $164.08 per share, at prices ranging from $163.38 to $164.36 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Reflects a weighted average sale price of $164.80 per share, at prices ranging from $164.38 to $165.35 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Reflects a weighted average sale price of $165.78 per share, at prices ranging from $165.40 to $166.11 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Reflects a weighted average sale price of $166.65 per share, at prices ranging from $166.51 to $167.36 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Reflects a weighted average sale price of $167.74 per share, at prices ranging from $167.56 to $168.10 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Reflects a weighted average sale price of $169.12 per share, at prices ranging from $168.82 to $169.41 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Shares held by Reporting Person's spouse. The Stock Options vest in equal annual installments over five years beginning on 09/24/2019, the first anniversary of the date of grant. /s/ Bruce A. Blefeld, Attorney-in-Fact 2021-06-17